<DOC>
	<DOCNO>NCT00617526</DOCNO>
	<brief_summary>The primary objective trial : • evaluate change baseline plasma viral load placebo one 4 dose regimen RDEA806 . The secondary objective : Efficacy - describe nadir plasma viral load - describe DAVG - ass proportion subject reach drop viral load 0.5 log , 1 log , reach undetectable viral load - ass plasma viral load decay rate - evaluate immunologic change ( measure CD4 CD8 cell ) - evaluate genotypic phenotypic pattern virus Pharmacokinetics - evaluate pharmacokinetics pharmacokinetic/pharmacodynamic relationship RDEA806 Safety - evaluate safety tolerability bid qd dose RDEA806 monotherapy</brief_summary>
	<brief_title>Naïve HIV POC Monotherapy Trial</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Documented chronic HIV1 infection HIV1 plasma viral load screen visit 5000 HIV1 RNA copies/ml Male , age 18 year less 65 year age Adequate method birth control Subject never receive antiretroviral agent ( NRTI , NNRTI , PI , entry inhibitor integrase inhibitor ) treatment HIV agree start antiretroviral therapy prior enrollment subject receive short course treatment le 14 day treatment least 8 week Subject primary mutation reverse transcriptase ( RT ) gene associate resistance RT inhibitor major mutation protease gene associate resistance PIs determine genotypic resistance test screen History suspicion alcohol drug abuse Investigator 's opinion may lead noncompliance CD4 count &lt; 350 cells/mm3 Life expectancy le 6 month Receipt investigational drug within 30 day prior trial drug administration Receipt vaccine within 30 day screen visit Acute HIV1 infection ( seroconversion illness ) Acute hepatitis A acute chronic hepatitis B C infection Currently active acquire immune deficiency syndrome ( AIDS ) define illness ( Category C condition accord Centers Disease Control [ CDC ] Classification System HIV Infection 1993 ) No clinically relevant laboratory abnormality Renal impairment : serum creatinine &gt; 1.5 x ULN Febrile illness within 120 hour prior dose History severe drug allergy hypersensitivity Significant cardiac dysfunction</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>HIV</keyword>
	<keyword>treatment naïve</keyword>
</DOC>